This website uses cookies
Read our Privacy policy and Terms of use for more information.
Long Form Content
Dec 13, 2024
•
11 min read
Investors sue BMS on alleged reneging on milestone payments, Novo Nordisk's Ozempic lands kidney disease-related label expansion in the EU, Expression Therapeutics has “promising” Ph1 hemophilia A gene therapy data, Keros Therapeutics stock plummets on PAH clinical trial holds due to pericardial effusion cases + 32 more stories
Dec 12, 2024
12 min read
Pair of (former) biotech CEOs convicted of fraud, Candel Therapeutics stock jumps on positive viral immunotherapy Ph3 data in prostate cancer, Angitia Biopharmaceuticals $120M Series C targeting musculoskeletal disorders, Q32 Bio stock collapses on "messy" trial results + 37 more stories
Dec 11, 2024
uniQure stock skyrockets on clear(er) path to accelerated approval, BioNTech's breast cancer bispecific dreams of dethroning Keytruda, Tasca Therapeutics launches with $52M to discover novel lipid-bound protein pockets, GSK and Relation partner on fibrotic disease and osteoarthritis drug discovery + 33 more stories
Dec 10, 2024
Gotta catch'em all (hematology clinical updates) at ASH 2024, Dimension's $500M second fund at the “interfaces of life science and technology”, Citryll's €85M Series B fuels inflammatory disease ambitions, Agios' discloses liver injuries from "very safe" mitapivat + 37 more stories
Dec 9, 2024
9 min read
Novo Holdings' Catalent acquisition gets go-ahead from EU regulators, Teva & Takeda divest generics joint venture to PE firm, bluebird bio touts positive long-term sickle cell disease gene therapy data, National Resilience layoffs + 24 more stories
Dec 6, 2024
8 min read
Atlas Venture closes $450M Fund XIV focused on biotech, Protara Therapeutics positive Ph2 cell therapy data launches stock upward, Nuvig Therapeutics $161M Series B for non-immune system suppressing autoimmune therapies, Eli Lilly & Amgen both announce $1B+ facility builds + 20 more stories
Dec 5, 2024
Eli Lilly's Zepbound beats Novo Nordisk's Wegovy in obesity head-to-head, Merus' mAb Bizengri nabs pancreatic and lung cancer approvals, Antag Therapeutics joins the obesity race with an $84M Series A, Novo Nordisk buys Novavax manufacturing site + 34 more stories
Dec 4, 2024
10 min read
Maze Therapeutics $115M Series D fuels kidney disease ambitions, Gilead buys ADC discovery option from Tubulis, Janux T-cell engager Ph1b dose escalation data launches stock 50%, GSK's hep B vaccine hopeful sputters in Ph1/2, insult to injury as Applied Therapeutics handed FDA warning letter + 29 more stories
Dec 3, 2024
Novartis signs up to $3B deal for PTC Huntington's asset, Senti Bio's stock launches 400%+ on early Ph1 CAR-NK data, Sanofi earmarks €1B for Beijing-based insulin manufacturing plant, KisoJi lands $41M in equity fuel for TROP2-targeting solid tumor clinical asset + 25 more stories
Dec 2, 2024
bluebird bio's Skysona blood cancer risk comes under FDA scrutiny, BeiGene lands a first-line Tevimbra (PD-1) approval, PTC Therapeutics to sell their PRV for $150M, BMS joins the 340B lawsuit party + 36 more stories
Nov 27, 2024
Roche paying a pretty penny for Poseida's allogeneic cell therapy ambitions, Amgen's MariTide weight loss Ph2 data isn't enough for investors, Cradle Bio $73M Series B for AI-driven protein design, Roche’s anti-TIGIT mAb misses in lung cancer Ph3 + 26 more stories
Nov 26, 2024
Cassava's much-controversial Alzheimer's hopeful flunks in Ph3, Alnylam whips out the priority review voucher for cardiomyopathy asset, Adcendo's ADC hopes get $135M injection, AstraZeneca touts Truqap prostrate cancer subtype Ph3 win + 27 more stories
